 |
|
Terazosin in the Treatment of Benign Prostatic Hyperplasia
Michael K. Brawer, MD;
George Adams, MD;
Howard Epstein, MD;
the Terazosin Benign Prostatic Hyperplasia Study Group
Arch Fam Med. 1993;2(9):929-935.
References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.
| |
1. Caine M, Pfau A, Perlberg S. The use of alpha adrenergic blockers in benign prostatic obstruction. Br J Urol. 1976;48:255-264.
PUBMED
2. Caine M. Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy. Urology. 1988;32(suppl):16-26.
PUBMED
3. Lepor H. Role of long-acting selective alpha-1 blockers in the treatment of benign prostatic hyperplasia. Urol Clin North Am. 1990;17:651-659.
PUBMED
4. Lepor H, Knapp-Maloney G, Sunshine H. A dose titration study evaluating terazosin, a selective, once-a-day  1-blocker for the treatment of symptomatic benign hyperplasia. J Urol. 1990;144:1393-1398.
PUBMED
5. Lepor H, Knapp-Maloney G, Wozniak-Petrofsky J. The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia. Int J Clin Pharmacol Ther Toxicol. 1989;27:392-397.
PUBMED
6. Fabricius PG, Weizert P, Dunzendorfer U, Mac Hannaford J, Maurath C. Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial. Prostate. 1990;3(suppl):85-93.
7. Dunzendorfer U. Clinical experience: symptomatic management of BPH with terazosin. Urology. 1988;32(suppl):27-31.
PUBMED
8. Lepor H, Auerbach S, Puras-Baez A, et al. A randomized, placebo controlled, multicentered study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol. 1992;148:1467-1474.
PUBMED
9. Boyarsky S, Jones G, Paulson D, Prout G. A new look at bladder obstruction by the Food and Drug Administration regulators: guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg. 1977;68:29-32.
10. von Garrelts B. Micturition in the normal male. Acta Chir Scand. 1957;114:197-210.
11. Siroky MB, Olsson CA, Krane RJ. The flow rate nomogram, II: clinical correlation. J Urol. 1980;123:208-210.
PUBMED
12. Siroky MS, Olsson CA, Krane RJ. The flow rate nomogram, I: development. J Urol. 1979;122:665-668.
PUBMED
13. Lepor H. Alpha1-adrenergic blockers in the medical management of benign pro-static hyperplasia. Curr Opin Urol. 1992;2:26-29.
14. Hedlund H, Andersson HE, Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol. 1983;130:275-278.
PUBMED
15. Kirby RS, Coppinger SWC, Corcoran MO, Chapple CR, Flannigan M, Milroy EJG. Prazosin in the treatment of prostatic obstruction: a placebo-controlled study. BrJ Urol. 1987;60:136-142.
16. Chapple CR, Christmas TJ, Milroy EJ. A twelve-week placebo-controlled study of prazosin in the treatment of prostatic obstruction. Urol Int. 1990;45(suppl):47-55.
PUBMED
17. Mantorana G, Giberti C, Damonte P, Ciprandi G, Dirienzo W, Giulana L. The effect of prazosin in benign hypertrophy: a placebo controlled double-blind study. Int Res Commun Sci J Med Sci. 1984;12:11.
18. Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978;50:551-554.
PUBMED
19. Gerstenberg T, Blaajerg J, Nielson ML, Clausen S. Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic hyperplasia: a urodynamic investigation. Invest Urol. 1980;18:29-31.
PUBMED
20. Brooks ME, Sidi AA, Hanani Y, Braf KF. Ineffectiveness of phenoxybenzamine in treatment of benign prostatic hypertrophy: a controlled study. Urology. 1983;21:474-478.
PUBMED
21. Ferrie BG, Paterson PJ. Phenoxybenzamine in prostatic hypertrophy: a double-blind study. Br J Urol. 1987;59:63-65.
PUBMED
22. Abrams PH, Shah PJ, Stone R, Choa RG. Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol. 1982;54:527-530.
PUBMED
23. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 1992;327:1185-1191.
ABSTRACT
24. Lange PH. Is the prostate pill finally here? N Engl J Med. 1992;327:1234-1236.
PUBMED
25. Luther RR. New perspectives on selective alpha 1 blockade. Am J Hypertens. 1989;2:729-735.
PUBMED
26. Cohen JD. Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents. Am Heart J. 1991;122:919-925.
PUBMED
|
